Biogen Company Profile (NASDAQ:BIIB)

About Biogen (NASDAQ:BIIB)

Biogen logoBiogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BIIB
  • CUSIP: 09062X10
  • Web: www.biogen.com
Capitalization:
  • Market Cap: $67.33 billion
  • Outstanding Shares: 211,431,000
Average Prices:
  • 50 Day Moving Avg: $300.47
  • 200 Day Moving Avg: $278.47
  • 52 Week Range: $244.28 - $330.00
P/E:
  • Trailing P/E Ratio: 20.8342
  • Foreward P/E Ratio: 13.74
  • P/E Growth: 2.2400
Sales & Book Value:
  • Annual Revenue: $11.72 billion
  • Price / Sales: 5.75
  • Book Value: $54.79 per share
  • Price / Book: 5.81
Profitability:
  • EBIDTA: $6.42 billion
  • Net Margins: 28.10%
  • Return on Equity: 37.42%
  • Return on Assets: 20.12%
Debt:
  • Debt-to-Equity Ratio: 0.51%
  • Current Ratio: 2.10%
  • Quick Ratio: 1.83%
Misc:
  • Average Volume: 1.36 million shs.
  • Beta: 0.77
  • Short Ratio: 2.28
 

Frequently Asked Questions for Biogen (NASDAQ:BIIB)

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) announced its quarterly earnings results on Tuesday, July, 25th. The company reported $5.04 EPS for the quarter, beating analysts' consensus estimates of $4.36 by $0.68. The company earned $3.08 billion during the quarter, compared to analyst estimates of $2.81 billion. Biogen had a return on equity of 37.42% and a net margin of 28.10%. The firm's revenue was up 6.4% on a year-over-year basis. During the same period in the prior year, the company earned $5.21 earnings per share. View Biogen's Earnings History.

When will Biogen make its next earnings announcement?

Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Biogen.

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of $20.80-21.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $20.37. The company issued revenue guidance of $11.5-11.8 billion, compared to the consensus revenue estimate of $11.40 billion.

Where is Biogen's stock going? Where will Biogen's stock price be in 2017?

25 brokers have issued 1 year price targets for Biogen's stock. Their forecasts range from $271.00 to $442.00. On average, they anticipate Biogen's stock price to reach $331.22 in the next twelve months. View Analyst Ratings for Biogen.

What are analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:

  • 1. Cantor Fitzgerald analysts commented, "A German patient treated for three years with Tysabri and then with a single dose of Ocrevus developed PML." (5/25/2017)
  • 2. Cowen and Company analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)
  • 3. Mizuho analysts commented, "We just started our Spinraza webinar … here’s a link to the slides pdf Rating Neutral Previous Rating No Change Price (4/17) $274.05 Price Target $290.00 Previous Price Target No Change LINK to slides for our Spinraza webinar (for folks who prefer a pdf copy): CLICK HERE Link to join webinar (just started): CLICK HERE We intend to blast a replay of the webinar after we finish. PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (4/18/2017)
  • 4. Instinet analysts commented, "We are initiating on BIIB with a Buy rating and $345 target price. We recommend owning BIIB shares over the next 12 months given limited 2017 downside to revenue forecasts and potential Spinraza launch upside. We estimate that a successful Spinraza launch will drive above-consensus revenues of $11.6bn in 2017 and $12.2bn in 2018, despite flat MS-franchise growth that may be impacted by emerging competition (Ocrevus). We anticipate this return to growth will drive modest revenue multiple expansion and strong GAAP EPS growth - to $19.41 in 2017 and $21.56 in 2018, yielding upside to our $345 target price." (3/1/2017)
  • 5. Jefferies Group LLC analysts commented, "This morning BIIB announced a settlement with FWP around Tecfidera IP. While we believe Street expectations were generally balanced going into the 3/17 decision (and we had assumed 50/50 prob. BIIB would be successful), commercial and some IPR risk remains, and recent focus has been more on Spinraza launch and Alzheimer’s, the terms look reasonable to us and help reduce an overhang." (1/18/2017)

Who are some of Biogen's key competitors?

Who are Biogen's key executives?

Biogen's management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board
  • Michel Vounatsos, Chief Executive Officer, Director
  • Gregory F. Covino, Interim Principal Financial Officer, Chief Accounting Officer, Vice President - Finance
  • Ginger Gregory Ph.D., Chief Human Resource Officer, Executive Vice President
  • Kenneth A. Di Pietro, Executive Vice President - Human Resources
  • Susan H. Alexander Esq., Executive Vice President, Chief Legal Officer and Corporate Secretary
  • Michael D. Ehlers M.D., Ph.D., Executive Vice President, Head - Research and Development
  • Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs
  • Jean-Paul Kress M.D., Executive Vice President, President - International and Head of Global Therapeutic Operations
  • Paul McKenzie Ph.D., Executive Vice President - Pharmaceutical Operations & Technology

Who owns Biogen stock?

Biogen's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.56%), Vanguard Group Inc. (6.87%), State Street Corp (4.60%), FMR LLC (2.89%), Northern Trust Corp (1.43%) and Alliancebernstein L.P. (1.14%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

Who sold Biogen stock? Who is selling Biogen stock?

Biogen's stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Winslow Capital Management LLC, Alliancebernstein L.P., Franklin Resources Inc., PointState Capital LP, Ameriprise Financial Inc., Bank of New York Mellon Corp and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Biogen stock in the last year include Adriana Karaboutis, Alfred Sandrock, Brian S Posner, Caroline Dorsa, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.

Who bought Biogen stock? Who is buying Biogen stock?

Biogen's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Manning & Napier Advisors LLC, FMR LLC, TIAA CREF Investment Management LLC, BlackRock Inc., LSV Asset Management, Parametric Portfolio Associates LLC and Samlyn Capital LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

How do I buy Biogen stock?

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of Biogen stock can currently be purchased for approximately $318.46.


MarketBeat Community Rating for Biogen (NASDAQ BIIB)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,135 (Vote Outperform)
Underperform Votes:  678 (Vote Underperform)
Total Votes:  1,813
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biogen (NASDAQ:BIIB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 12 Hold Ratings, 12 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $331.22 (4.01% upside)

Analysts' Ratings History for Biogen (NASDAQ:BIIB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017Raymond James Financial, Inc.DowngradeStrong-Buy -> Market Perform$244.28 -> $319.00LowView Rating Details
9/20/2017SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$360.00LowView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$319.00MediumView Rating Details
9/13/2017BMO Capital MarketsBoost Price TargetMarket Perform$328.00 -> $377.00LowView Rating Details
9/13/2017MizuhoReiterated RatingNeutral$274.00 -> $319.00MediumView Rating Details
8/25/2017Robert W. BairdReiterated RatingHold$290.00LowView Rating Details
8/16/2017Goldman Sachs Group, Inc. (The)UpgradeBuy -> Conviction-Buy$338.00LowView Rating Details
7/27/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
7/26/2017Morgan StanleyReiterated RatingEqual Weight$301.00 -> $311.00LowView Rating Details
7/26/2017Deutsche Bank AGReiterated RatingBuy$315.00 -> $319.00LowView Rating Details
7/26/2017Leerink SwannReiterated RatingMarket Perform$304.00 -> $338.00HighView Rating Details
7/14/2017Credit Suisse GroupSet Price TargetHold$300.00LowView Rating Details
7/11/2017Jefferies Group LLCReiterated RatingHold -> Hold$310.00LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
5/25/2017Sanford C. BernsteinReiterated RatingOutperformLowView Rating Details
5/25/2017Cantor FitzgeraldReiterated RatingHold$277.00LowView Rating Details
5/15/2017Piper Jaffray CompaniesSet Price TargetBuy$332.00 -> $442.00LowView Rating Details
4/26/2017Stifel NicolausBoost Price TargetHold$265.00 -> $280.00MediumView Rating Details
4/23/2017Barclays PLCReiterated RatingOverweight$380.00 -> $360.00MediumView Rating Details
4/4/2017Citigroup Inc.Boost Price TargetBuy$305.00 -> $315.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$223.03 -> $345.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
1/30/2017HC WainwrightReiterated RatingBuy$360.00N/AView Rating Details
1/18/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
9/22/2016Bank of America CorporationReiterated RatingBuy$374.00N/AView Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
6/8/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$344.00N/AView Rating Details
9/23/2015Oppenheimer Holdings, Inc.Reiterated RatingSector PerformN/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Biogen (NASDAQ:BIIB)
Earnings by Quarter for Biogen (NASDAQ:BIIB)
Earnings History by Quarter for Biogen (NASDAQ BIIB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$5.61N/AView Earnings Details
7/25/2017Q2 2017$4.36$5.04$2.81 billion$3.08 billionViewN/AView Earnings Details
4/25/2017Q1 2017$4.97$5.20$2.73 billion$2.81 billionViewN/AView Earnings Details
1/26/2017Q416$4.96$5.04$2.94 billion$2.87 billionViewN/AView Earnings Details
10/26/2016Q316$4.97$5.19$2.91 billion$2.96 billionViewListenView Earnings Details
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.74$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.80$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biogen (NASDAQ:BIIB)
2017 EPS Consensus Estimate: $20.36
2018 EPS Consensus Estimate: $24.24
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$4.47$5.03$4.75
Q2 20173$3.92$4.11$4.04
Q3 20174$5.69$6.16$5.92
Q4 20175$4.94$6.05$5.65
Q1 20182$5.70$5.88$5.79
Q2 20182$5.95$6.22$6.09
Q3 20182$6.11$6.17$6.14
Q4 20182$6.20$6.24$6.22
Q1 20191$6.30$6.30$6.30
Q2 20191$6.53$6.53$6.53
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Biogen (NASDAQ:BIIB)
Insider Ownership Percentage: 0.32%
Institutional Ownership Percentage: 87.65%
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2017Susan H AlexanderEVPSell4,974$290.01$1,442,509.74View SEC Filing  
7/19/2017Susan H AlexanderEVPSell7,758$285.00$2,211,030.00View SEC Filing  
6/9/2017Brian S PosnerDirectorSell1,084$256.31$277,840.04View SEC Filing  
5/1/2017Michel VounatsosCEOBuy1,402$271.35$380,432.70View SEC Filing  
4/27/2017Alexander J. DennerDirectorBuy73,858$278.50$20,569,453.00View SEC Filing  
4/25/2017Paul J ClancyVPSell9,892$290.00$2,868,680.00View SEC Filing  
4/3/2017Alfred SandrockCMOSell1,981$274.08$542,952.48View SEC Filing  
3/13/2017Paul J ClancyVPSell9,891$291.55$2,883,721.05View SEC Filing  
2/27/2017Michel VounatsosCEOBuy1,333$285.39$380,424.87View SEC Filing  
1/9/2017Robert W PangiaDirectorSell5,450$295.39$1,609,875.50View SEC Filing  
10/4/2016Adriana KaraboutisEVPSell262$311.94$81,728.28View SEC Filing  
10/3/2016Adriana KaraboutisEVPSell380$313.00$118,940.00View SEC Filing  
9/22/2016Caroline DorsaDirectorSell27,570$314.00$8,656,980.00View SEC Filing  
7/21/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.00View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.00View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.70View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.38View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.00View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.21View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.19View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.60View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.70View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.52View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.92View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.08View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.00View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.00View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.15View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.88View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.00View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.66View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.00View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.00View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.00View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.45View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.43View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.24View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.18View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.16View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.80View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.35View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.36View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.80View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.00View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.00View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.50View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.00View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.00View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.00View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.98View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.10View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.00View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.60View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.80View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Biogen (NASDAQ:BIIB)
Latest Headlines for Biogen (NASDAQ:BIIB)
Source:
DateHeadline
americanbankingnews.com logoBiogen Inc. (BIIB) Expected to Post Q3 2017 Earnings of $5.79 Per Share
www.americanbankingnews.com - September 22 at 6:56 AM
americanbankingnews.com logoBiogen Inc. (BIIB) Cut to Market Perform at Raymond James Financial, Inc.
www.americanbankingnews.com - September 21 at 8:56 PM
finance.yahoo.com logoBiogen: Buy or Hold?
finance.yahoo.com - September 21 at 4:19 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Coverage Initiated by Analysts at SunTrust Banks, Inc.
www.americanbankingnews.com - September 20 at 9:46 AM
investorplace.com logoProfit From the Biogen Inc (BIIB) Stock Dip! - Investorplace.com
investorplace.com - September 20 at 2:37 AM
investorplace.com logoProfit From the Biogen Inc (BIIB) Stock Dip!
investorplace.com - September 19 at 11:12 AM
americanbankingnews.com logoBiogen Inc. (BIIB) Now Covered by Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 11:06 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Price Target Raised to $377.00
www.americanbankingnews.com - September 13 at 2:22 PM
americanbankingnews.com logoMizuho Reiterates "Neutral" Rating for Biogen Inc. (BIIB)
www.americanbankingnews.com - September 13 at 12:26 PM
nasdaq.com logoBIIB January 2020 Options Begin Trading - Nasdaq
www.nasdaq.com - September 12 at 4:49 PM
finance.yahoo.com logoBiogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
finance.yahoo.com - September 12 at 4:49 PM
finance.yahoo.com logoWhat Is Biogen Inc’s (BIIB) Share Price Doing?
finance.yahoo.com - September 12 at 4:49 PM
nasdaq.com logoBiogen Reaches Analyst Target Price
www.nasdaq.com - September 11 at 5:13 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Stock Rating Upgraded by Vetr Inc.
www.americanbankingnews.com - September 9 at 11:22 PM
americanbankingnews.com logo Brokerages Expect Biogen Inc. (BIIB) to Announce $5.61 Earnings Per Share
www.americanbankingnews.com - September 7 at 10:24 PM
benzinga.com logoWhy It's Useful To Know A Company's Competitors When Trading - Benzinga
www.benzinga.com - September 6 at 4:15 AM
americanbankingnews.com logoBiogen (BIIB) vs. Peregrine Pharmaceuticals (PPHM) Head-To-Head Review
www.americanbankingnews.com - September 4 at 10:12 PM
americanbankingnews.com logoVetr Inc. Downgrades Biogen Inc. (BIIB) to Hold
www.americanbankingnews.com - September 4 at 1:16 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Cut to "Hold" at ValuEngine
www.americanbankingnews.com - September 3 at 9:00 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 2 at 2:38 PM
finanznachrichten.de logoPro-Trader Daily: Featured Company News - Ionis Earns Regulatory Milestone Payment from Biogen for SPINRAZA
www.finanznachrichten.de - September 1 at 4:49 PM
finance.yahoo.com logoThese 4 Biotechs Just Moved Into Buy Zones; Is This Giant Next?
finance.yahoo.com - August 31 at 9:27 PM
americanbankingnews.com logoHead-To-Head Review: Biogen (BIIB) & Baxalta (BXLT)
www.americanbankingnews.com - August 31 at 4:24 PM
finance.yahoo.com logoBiogen's Alzheimer's Drug Shows Promise — Could It Break Out?
finance.yahoo.com - August 29 at 4:51 PM
nasdaq.com logoMonday Sector Leaders: Healthcare, Technology & Communications - Nasdaq
www.nasdaq.com - August 28 at 9:36 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Rating Reiterated by Robert W. Baird
www.americanbankingnews.com - August 28 at 2:28 PM
americanbankingnews.com logoFY2019 EPS Estimates for Biogen Inc. Boosted by William Blair (BIIB)
www.americanbankingnews.com - August 28 at 10:58 AM
finance.yahoo.com logoConsider This Before You Buy Biogen
finance.yahoo.com - August 27 at 4:09 PM
finance.yahoo.com logoBiogen's Humira Biosimilar Imraldi Gets Approval in EU - Yahoo Finance
finance.yahoo.com - August 26 at 4:13 PM
rttnews.com logoADMS Soars On FDA Nod, EARS Gets An Earful, Thumbs Up For BIIB's Humira Biosim
www.rttnews.com - August 25 at 5:01 AM
finance.yahoo.com logoIMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union
finance.yahoo.com - August 24 at 9:39 PM
finance.yahoo.com logoSamsung, Biogen version of AbbVie's Humira approved in Europe
finance.yahoo.com - August 24 at 9:39 PM
finance.yahoo.com logoIonis Reports Revenue Growth in 2Q17
finance.yahoo.com - August 23 at 9:46 PM
americanbankingnews.com logoZacks: Analysts Anticipate Biogen Inc. (BIIB) Will Post Quarterly Sales of $3.00 Billion
www.americanbankingnews.com - August 22 at 3:46 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Lifted to "Conviction-Buy" at Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - August 20 at 11:58 PM
americanbankingnews.com logo Brokerages Expect Biogen Inc. (BIIB) to Announce $5.61 EPS
www.americanbankingnews.com - August 20 at 6:16 AM
finance.yahoo.com logoGoldman has a new favorite biotech because of potential A...
finance.yahoo.com - August 18 at 4:35 PM
finance.yahoo.com logoGoldman has a new favorite biotech because of potential Alzheimer's blockbuster
finance.yahoo.com - August 18 at 3:57 AM
americanbankingnews.com logoBiogen Inc. (BIIB) Upgraded by Vetr Inc. to Strong-Buy
www.americanbankingnews.com - August 18 at 12:34 AM
nasdaq.com logoNotable Thursday Option Activity: DE, NVDA, BIIB - Nasdaq
www.nasdaq.com - August 17 at 10:56 PM
finance.yahoo.com logoBiogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List
finance.yahoo.com - August 16 at 5:06 PM
nasdaq.com logoSteven Cohen Buys Biogen Inc, Alphabet Inc, Comcast Corp, Sells Facebook Inc, Advance Auto ...
www.nasdaq.com - August 15 at 5:23 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Raised to Strong-Buy at Vetr Inc.
www.americanbankingnews.com - August 11 at 12:38 AM
americanbankingnews.com logoComparing Myovant Sciences (MYOV) and Biogen (NASDAQ:BIIB)
www.americanbankingnews.com - August 10 at 10:24 PM
nasdaq.com logoNoteworthy ETF Inflows: VHT, TMO, BIIB, AET - Nasdaq
www.nasdaq.com - August 8 at 4:18 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 8 at 2:44 PM
americanbankingnews.com logoBiogen Inc. (BIIB) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - August 6 at 12:42 PM
nasdaq.com logoSee Which Of The Latest 13F Filers Holds Biogen - Nasdaq
www.nasdaq.com - August 4 at 4:50 PM
americanbankingnews.com logoResearch Analysts Offer Predictions for Biogen Inc.'s Q1 2019 Earnings (BIIB)
www.americanbankingnews.com - August 3 at 4:40 PM
americanbankingnews.com logoCantor Fitzgerald Comments on Biogen Inc.'s FY2017 Earnings (NASDAQ:BIIB)
www.americanbankingnews.com - August 2 at 10:52 AM

Social

Chart

Biogen (BIIB) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff